Chelsea Therapeutics, Lundbeck deal

H. Lundbeck began its tender offer to acquire Chelsea for up to $7.94 per share, or about $626.8 million. Chelsea shareholders will receive $6.44 per share in cash, or about $508.3 million, and a cont...